Deals
The pact between Madrigal Pharmaceuticals and Ruzhou Ribo Life Sciences could complement the former’s Rezdiffra, the first FDA-approved therapy for MASH. That drug made $287.3 million in the third quarter of 2025.
FEATURED STORIES
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets.
Buying vaccine biotech Dynavax was an easy choice for Sanofi despite anti-vaccine moves by the Trump administration.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
AcelRx Pharmaceuticals, headquartered in Redwood City, California, is buying Watertown, Massachusetts-based TetraPhase Pharmaceuticals for $14.4 million.
Consumer healthcare company HRA Pharma grew their total group revenues by 20.8% in 2019 with EBITDA growing by 30%
The new company is focused on tapping into the powers of the immune system to address numerous diseases.
Numab Therapeutics announced the closing of its Series B financing round at a total volume of CHF 22M. New investors in this round included 3SBio/Sunshine Guojian, Mitsubishi UFJ Capital Co., Ltd. and Eisai Co., Ltd. as well as Numab’s board member Dr. Daniel Vasella.
Mergers and acquisitions in the pharmaceutical industry are not only a positive for the company that has made a bid for another company, but it is also good for the industry as a whole because of increases in efficiency across the entire field.
Deerfield Management placed Melinta’s assets up for auction, but no other companies made competing bids, leaving Deerfield in control of the company’s assets.
On Tuesday, the European Commission gave the green light to the merger following the divestiture of an investigational autoimmune treatment.
Polarean Imaging plc announces that it has issued 232,010 new ordinary shares of £0.00037 each in the capital of the Company at par value, following the exercise of warrants by Amphion Innovations plc.
Qiagen manufactures diagnostic tests for a variety of diseases including cancer and, currently, the coronavirus that causes COVID-19.
“This agreement builds on Gilead’s presence in immuno-oncology and adds significant potential to our clinical pipeline,” said Daniel O’Day, Gilead’s chairman and chief executive officer.